Skip to content

cucurbita, probiotic yogurt intake and diabetic type 2

effect of cucurbita and probiotic yogurt intake on glycemic, inflammatory indices, blood lipid and anthropometric in diabetic patient.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT2013041311763N7
Enrollment
80
Registered
2013-12-12
Start date
2013-04-01
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

????? ??????. Non-insulin-dependent diabetes mellitus

Interventions

Intervention 1: cucurbita group: daily intake of 100 gr cucurbita(on medium cucurbita) duration 2 months along with lunch to be intake raw. Intervention 2: probiotic yoghurt: daily intake of 150 gr pr
Treatment - Other
Treatment - Drugs
cucurbita group: daily intake of 100 gr cucurbita(on medium cucurbita) duration 2 months along with lunch to be intake raw.
probiotic yoghurt: daily intake of 150 gr probiotic yoghurt (approximately 7 teaspoons) duration 2 months along with lunch.
cucurbita and probiotic yoghurt group: daily intake of 100 gr cucurbita (on cucurbita medium) and 150 gr probiotic yoghurt (approximately) duration 2 months along with lunch.
control group using a normal diet suitable for diabetes.

Sponsors

Vice Chancellor for Research, Isfahan University of Medical Scien
Lead Sponsor

Eligibility

Sex/Gender
All
Age
25 Years to 70 Years

Inclusion criteria

Inclusion criteria: all prediabetic patients at the age range of 25 to 70 years old ? fsting plasma glucose uper 126 are included in the study. patients with chronic hepatic? renal ? heart diseases are not included in the study? patients who have allergic responses to probiotics yogurt or cucurbita or those who want to give up following the study or those who have not taken their probiotics yogurt or cucurbita will be excluded from the study.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Fasting blood glucose. Timepoint: the first day of the study and the last day of 8th week. Method of measurement: Colorimetry.;Glycated hemoglobin(HbA1C). Timepoint: the first day of the study and the last day of 8th week. Method of measurement: Ion exchange chromatography.;Total serum cholestrol. Timepoint: the first day of the study and the last day of 8th week. Method of measurement: Enzymatic assay with autoanalyser.;Serum triglycerides. Timepoint: the first day of the study and the last day of 8th week. Method of measurement: Enzymatic assay with autoanalyser.;Serum low density lipoprotein. Timepoint: the first day of the study and the last day of 8th week. Method of measurement: Enzymatic assay with autoanalyser.;Serum High density lipoprotein. Timepoint: The first day of the study and the last day of 8th week. Method of measurement: Enzymatic assay with autoanalyser.;High sensitive C- Reactive Protein. Timepoint: The first day of the study and the last day of 8th week. Method of measurement: Turbidimetric Method.

Secondary

MeasureTime frame
Body compisition. Timepoint: the first day of the study and the last day of 8th week. Method of measurement: BIA method.;Blood pressure. Timepoint: The first day of the study and the last day of 8th week. Method of measurement: Presure indicator.

Countries

Iran (Islamic Republic of)

Contacts

Public Contactazadeh.bayat

Isfahan University Of Medical Sciences

royan8304@yahoo.com+98 31 1792 2110

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026